MDxHealth (MDXH) Resumen de Acciones
MDxHealth SA, empresa de diagnóstico de precisión en fase comercial, ofrece soluciones urológicas en Estados Unidos, Europa y a escala internacional. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 5/6 |
| Crecimiento futuro | 0/6 |
| Rendimiento pasado | 0/6 |
| Salud financiera | 1/6 |
| Dividendos | 0/6 |
Recompensas
Análisis de riesgos
+ 1 riesgos adicionales
MDXH Community Fair Values
Create NarrativeSee what 12 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de MDxHealth SA
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$0.63 |
| Máximo en las últimas 52 semanas | US$5.33 |
| Mínimo de 52 semanas | US$0.40 |
| Beta | -501643.69 |
| Cambio en 1 mes | -15.22% |
| Variación en 3 meses | 22.35% |
| Cambio de 1 año | -86.54% |
| Variación en 3 años | n/a |
| Variación en 5 años | -95.74% |
| Variación desde la OPV | -99.28% |
Noticias y actualizaciones recientes
MDXH: Upcoming Study Readouts Will Refocus Pure-Play Prostate Cancer Potential
Analysts have adjusted their average MDxHealth price target from about $5.00 to roughly $3.00 following updated models after recent financings and product changes. They continue to describe the company as a focused prostate cancer diagnostics player with important study readouts expected in the future.
MDXH: Upcoming Clinical Readouts Will Trigger Reassessment Of Depressed Share Price
Analysts have reduced their price targets for MDxHealth to a range centered around $2, reflecting updated models after the Resolve wind-down, the transfer of liabilities to Novitas, and recent equity offerings, while still citing the company's positioning in prostate cancer diagnostics as a key support for their long term thesis. Analyst Commentary Recent research updates on MDxHealth focus on how the Resolve wind down, the transfer of related liabilities, and new equity issuance feed into valuation, while also highlighting the company’s role in prostate cancer diagnostics.MDXH: Upcoming Clinical Readouts Will Drive Reassessment Of Depressed Share Price
Analysts have reduced their price target on MDxHealth stock to $3 from $5, highlighting the impact of the increased share count while still pointing to upcoming clinical readouts and recent study publications as key supports for the revised outlook. What's in the News for MDxHealth MDxHealth issued earnings guidance for 2026 with expected revenue in a range of US$110 million to US$115 million.Recent updates
MDXH: Upcoming Study Readouts Will Refocus Pure-Play Prostate Cancer Potential
Analysts have adjusted their average MDxHealth price target from about $5.00 to roughly $3.00 following updated models after recent financings and product changes. They continue to describe the company as a focused prostate cancer diagnostics player with important study readouts expected in the future.MDXH: Upcoming Clinical Readouts Will Trigger Reassessment Of Depressed Share Price
Analysts have reduced their price targets for MDxHealth to a range centered around $2, reflecting updated models after the Resolve wind-down, the transfer of liabilities to Novitas, and recent equity offerings, while still citing the company's positioning in prostate cancer diagnostics as a key support for their long term thesis. Analyst Commentary Recent research updates on MDxHealth focus on how the Resolve wind down, the transfer of related liabilities, and new equity issuance feed into valuation, while also highlighting the company’s role in prostate cancer diagnostics.MDXH: Upcoming Clinical Readouts Will Drive Reassessment Of Depressed Share Price
Analysts have reduced their price target on MDxHealth stock to $3 from $5, highlighting the impact of the increased share count while still pointing to upcoming clinical readouts and recent study publications as key supports for the revised outlook. What's in the News for MDxHealth MDxHealth issued earnings guidance for 2026 with expected revenue in a range of US$110 million to US$115 million.
MDXH: Future Upside Will Hinge On Resolving The 10.4m Medicare Recoupment
Analysts have reset expectations for MDxHealth, cutting price targets from as high as $9 to a range of $1.50 to $5, as they factor in weaker Q1 results, the exit from the Resolve UTI business, and reimbursement uncertainty that affects revenue growth, profit margin assumptions, and the future P/E multiple. Analyst Commentary Recent Street commentary around MDxHealth reflects a more cautious tone, with several bearish analysts reassessing the risk profile after weaker Q1 results, the planned exit from the Resolve UTI business, and questions around Medicare reimbursement.MDXH: Resolve Exit And Medicare Review Will Reset Prostate Cancer Focus
Analysts have sharply reduced their price targets on MDxHealth, with cuts such as $7 to $1.50, $9 to $5, and $7 to $4, reflecting weaker Q1 revenue, lowered guidance, and the exit of the Resolve UTI business following reimbursement and recoupment disputes. Analyst Commentary Recent research on MDxHealth highlights a mix of caution and optimism, with analysts reacting to weaker Q1 revenue, revised guidance, and the exit of the Resolve UTI business.MDXH: Resolve Exit And Medicare Review Will Refocus On Prostate Cancer
Analysts have cut their fair value estimate for MDxHealth from $9.00 to $5.00, citing reduced revenue growth assumptions, a higher discount rate, and a lower future P/E multiple after the Q1 miss, the Resolve exit, and reimbursement uncertainties. Analyst Commentary Recent Street research on MDxHealth reflects a reset in expectations after the Q1 shortfall, the Resolve exit, and reimbursement questions, but also highlights areas where analysts still see potential for execution and valuation recovery.MDXH: Future Upside Will Depend On Resolving The 10.4m Medicare Dispute
Analysts have reduced their fair value estimate for MDxHealth from $4.20 to $1.00 following weak Q1 results, lower revenue guidance, the discontinuation of the Resolve UTI test, and uncertainty surrounding a $10.4m Medicare recoupment notice and the closure of the related Texas lab. Analyst Commentary on MDxHealth Recent Street research on MDxHealth highlights a clear shift toward caution, with several bearish analysts cutting price targets and reassessing the risk profile after the weak Q1 update, reduced revenue guidance, the Medicare recoupment notice of $10.4m, and the decision to close the Texas lab tied to the Resolve UTI test.MDxHealth SA (NASDAQ:MDXH) Looks Inexpensive After Falling 28% But Perhaps Not Attractive Enough
MDxHealth SA ( NASDAQ:MDXH ) shareholders won't be pleased to see that the share price has had a very rough month...Rentabilidad de los accionistas
| MDXH | US Biotechs | Mercado US | |
|---|---|---|---|
| 7D | -10.9% | 0.3% | -0.1% |
| 1Y | -86.5% | 36.3% | 11.9% |
Rentabilidad vs. Industria: Los resultados de MDXH fueron inferiores a los de la industria US Biotechs, que obtuvo un rendimiento del 36.3% el año pasado.
Rentabilidad vs. Mercado: MDXH obtuvo unos resultados inferiores a los del mercado US, que fueron del 11.9% el año pasado.
Volatilidad de los precios
| MDXH volatility | |
|---|---|
| MDXH Average Weekly Movement | 24.2% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in US Market | 15.1% |
| 10% least volatile stocks in US Market | 2.9% |
Precio estable de las acciones: El precio de las acciones de MDXH ha sido volátil durante los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de MDXH ha aumentado de 16% a 24% en el último año.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2003 | 364 | Mike McGarrity | mdxhealth.com |
MDxHealth SA, empresa de diagnóstico de precisión en fase comercial, ofrece soluciones urológicas en Estados Unidos, Europa y a escala internacional. Las soluciones de análisis de la empresa incluyen Confirm mdx for prostate cancer tissue test, que valida una prueba epigenética que orienta la detección de cáncer de próstata oculto en tejido negativo de un paciente sometido previamente a biopsia; ExoD, un análisis de orina no invasivo para evaluar el riesgo de padecer clínicamente cáncer de próstata; y Resolve mdx for urinary tract infection, que identifica opciones antibióticas eficaces personalizadas contra la infección del paciente. Ofrece una puntuación genómica de la próstata, que proporciona perspectivas genómicas personalizadas a médicos y pacientes que navegan por las complejidades del diagnóstico y el tratamiento del cáncer de próstata.
Resumen de fundamentos de MDxHealth SA
| Estadísticas fundamentales de MDXH | |
|---|---|
| Capitalización bursátil | US$60.11m |
| Beneficios(TTM) | -US$36.43m |
| Ingresos (TTM) | US$114.02m |
¿Está MDXH sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de MDXH | |
|---|---|
| Ingresos | US$114.02m |
| Coste de los ingresos | US$42.35m |
| Beneficio bruto | US$71.67m |
| Otros gastos | US$108.10m |
| Beneficios | -US$36.43m |
Últimos beneficios comunicados
Jun 30, 2026
Próxima fecha de beneficios
Nov 12, 2026
| Beneficios por acción (BPA) | -0.38 |
| Margen bruto | 62.86% |
| Margen de beneficio neto | -31.95% |
| Ratio deuda/patrimonio | -317.1% |
¿Cómo se ha desempeñado MDXH a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/09/21 19:53 |
| Precio de las acciones al final del día | 2026/09/18 00:00 |
| Beneficios | 2026/06/30 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
MDxHealth SA está cubierta por 14 analistas. 6 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Michael Ruzic-Gauthier | Berenberg |
| Mark Massaro | BTIG |
| William Bonello | Craig-Hallum Capital Group LLC |